Deep Healthcare Coverage and Industry Insights

Andrew Berens, M.D., is a Senior Research Analyst at Leerink Partners covering Targeted Oncology.

Prior to joining the Firm in 2018, Dr. Berens was an Executive Director and Senior Biotechnology Research Analyst at Morgan Stanley focusing on mid- and small-cap biotechnology companies. He practiced as an emergency medicine physician for a decade before starting his career in equity research. He also worked in the pharma industry at Ikaria Pharmaceuticals, where he was a Senior Director in business development, leading search and development efforts. In 2017 he was named a Runner Up in Institutional Investor’s 2017 All–America Research Team for Biotechnology/Mid- & Small-Cap.

Dr. Berens earned his undergraduate degree in English Literature from Tulane University, his MBA degrees from Columbia Business School and London Business School, and his M.D. from Emory University.

Jonathan Chang, Ph.D., CFA is a Senior Research Analyst at Leerink Partners covering Emerging Oncology. He has been an important contributor to the Firm’s biotechnology research product and insights.

Jonathan joined the Firm in 2013 as an Associate supporting the Firm’s senior oncology biotechnology research team and in 2016, he assumed research coverage of several important emerging biotechnology companies. In 2018, he was named a Rising Star in Institutional Investor’s 2018 All-America Research Team for Biotechnology/Mid- & Small-Cap.

He earned a Ph.D. in Pharmacology from Cornell University, an M.A. in Biotechnology from Columbia University, and an Honors B.Sc. in Genes, Genetics, and Biotechnology from the University of Toronto. Dr. Chang is a CFA charter holder.

Michael Cherny is a Senior Managing Director and Senior Research Analyst at Leerink Partners covering Healthcare Technology and Distribution.

Prior to joining the Firm in 2023, Mr. Cherny’s most recent role was at Bank of America Merrill Lynch where he was Managing Director / Healthcare Technology & Distribution Analyst. Prior to Bank of America Merrill Lynch, Mr. Cherny was the Healthcare Technology & Distribution Analyst at UBS Securities and held roles at Evercore ISI and Deutsche Bank within the healthcare and technology sector. Mr. Cherny has been consistently ranked in the Extel survey (formerly Institutional Investor) for the Health Care Technology & Distribution group since 2019, including being ranked #1 in 2022-2023.

He earned his bachelor’s degree in business administration from Emory University.

Mani Foroohar, M.D., is a Senior Research Analyst within our Therapeutics team focusing on Genetic Medicines.

Dr. Foroohar joined Leerink Partners from Aptigon Capital, a Citadel Company, where he most recently was a Therapeutics Analyst focused on U.S. and EU biotechnology, major pharmaceuticals and specialty pharmaceuticals sectors. Prior to Aptigon, he was an Analyst at Green Owl Capital Management and an Assistant Vice President of Equity Research at Barclays. In 2013, Dr. Foroohar co-founded Cellanyx Diagnostics, a company developing a proprietary live tumor cell, phenotypic platform for precision risk stratification in cancer to inform clinical treatment decision-making.

Dr. Foroohar holds a B.S. from UCLA, an M.D. from Stanford, where he was a Howard Hughes Medical Institute Research Fellow in the Department of Genetics, and an MBA from Columbia.

Marc Goodman is a Senior Research Analyst at Leerink Partners covering Neuroscience and Ophthalmology.

Prior to joining the Firm in 2018, Mr. Goodman was most recently a Managing Director and U.S. Healthcare Analyst at UBS Investment Bank, where he focused on the large-cap and specialty pharmaceuticals sectors. Prior to UBS, Mr. Goodman covered the specialty pharmaceuticals and generics sectors for over 15 years as a Managing Director at Crédit Suisse AG and as an Executive Director at Morgan Stanley. Mr. Goodman has been ranked by Institutional Investor as a top analyst in Specialty Pharmaceuticals for well over a decade and has expanded his coverage and interests into global and emerging biopharmaceutical companies in recent years.

Mr. Goodman earned a B.A. in Economics from Tufts University and an MBA. from The Ohio State University.

Daina Graybosch, Ph.D., is a Senior Research Analyst at Leerink Partners covering Immuno-Oncology.

Prior to joining the Firm in 2018, Dr. Graybosch worked at McKinsey & Company as a Senior Expert and Head of McKinsey’s Center for Asset Optimization, as well as the U.S. Head of the McKinsey Cancer Center. In these roles, Dr. Graybosch developed several McKinsey solutions that applied data and advanced analytics to pharmaceutical development decisions. During her 11 years at McKinsey, Dr. Graybosch built deep oncology expertise through work with companies across the pharmaceutical, diagnostic, academic medical center, and genomic/data sectors.

Dr. Graybosch earned dual B.S. degrees in Biology and Chemistry from the University of Utah and a Ph.D. in Chemistry and Chemical Biology from Harvard University.

Mike Kratky, CFA is a Senior Research Analyst at Leerink Partners covering Medical Devices and Technology.

Prior to joining the Firm in 2018, Mr. Kratky worked in various roles at B. Riley FBR, Nasdaq, and MKM Partners. Mr. Kratky initially joined the Firm as an Associate focused on the immunology and inflammation space and was promoted to Vice President before leaving the Firm in March 2020. Mr. Kratky subsequently spent one year at Verition Fund Management and rejoined Leerink Partners in March 2021.

Mr. Kratky earned a B.A. in Economics from Colgate University and holds the Chartered Financial Analyst designation.

Whit Mayo is a Senior Managing Director and Senior Research Analyst at Leerink Partners covering Healthcare Providers and Managed Care.

Prior to joining the Firm in 2021, Mr. Mayo served as a Managing Director at UBS. Prior to UBS, Mr. Mayo covered the healthcare providers and managed care sector at Baird and Stephens Inc. In 2020, Mr. Mayo was ranked by Institutional Investor on the All-America Research Team in the Health Care Facilities and Managed Care category.

Mr. Mayo earned a B.A. in Economics from Sewanee, The University of the South.

David Risinger, CFA is a Senior Managing Director and Senior Research Analyst at Leerink Partners covering Diversified Biopharmaceuticals.

Prior to joining the Firm in 2022, Mr. Risinger served as Head of U.S. Major and Specialty Pharmaceuticals Equity Research at Morgan Stanley & Co. Prior to Morgan Stanley, Mr. Risinger was Head of Global Healthcare Research and Senior U.S. Pharmaceutical Analyst at Merrill Lynch & Co. He began his Wall Street career at Dillon, Read & Co. Mr. Risinger has been a top-ranked analyst by Institutional Investor for decades, including achieving Runner-Up rankings in both Major Pharmaceuticals and Specialty Pharmaceuticals in 2021.

Mr. Risinger earned a B.A. in Political Science from Bucknell University and holds the Chartered Financial Analyst designation.

Roanna Ruiz, Ph.D., is a Senior Research Analyst at Leerink Partners covering Biopharma, Cardiovascular, Endocrine Disorders, and Infectious Disease.

Prior to joining the Firm in 2018, Dr. Ruiz held equity research roles at UBS and H.C. Wainwright. Previously, Dr. Ruiz spent two years in pharmaceutical industry consulting at IQVIA, where she worked on M&A, product launch strategy, and pricing and reimbursement projects. Prior to covering the IDECV sectors, Dr. Ruiz was a core member of the Firm’s Neuroscience team, delivering science-forward, deep-dive fundamental research to clients.

Dr. Ruiz earned a B.S. in Engineering Sciences from Harvard University and a Ph.D. in Biomedical Engineering from Cornell University.

Joseph Schwartz is a Senior Research Analyst at Leerink Partners covering Rare Diseases.

Prior to joining the Firm in 2003, Mr. Schwartz provided economic and strategic consulting services to biotechnology and pharmaceutical companies with Charles River Associates. Earlier in his career, he held equity research positions at SG Cowen, State Street Research, and J.P. Morgan, where he analyzed the fundamental performance drivers of investments in the health care, retail, consumer, media, and entertainment sectors. Mr. Schwartz was named #1 Stock Picker for Pharmaceuticals in the 2011 FT/StarMine Analyst Awards. In 2010, he earned the Wall Street Journal’s #1 ranking for biotech stock picking as part of its “Best on the Street” analysts survey, which topped his #2 ranking in the Journal’s 2008 “Best on the Street” rankings.

Mr. Schwartz earned a B.A. in Economics from Colby College and an MBA from Babson College.

Thomas J. Smith is a Senior Research Analyst at Leerink Partners covering Immunology and Metabolism.

Prior to joining the Firm in 2018, Mr. Smith was a Vice President and Research Analyst at Morgan Stanley, where he covered leading and emerging biopharmaceutical companies across multiple therapeutic areas, including oncology, NASH, and women’s health. Prior to Morgan Stanley, Mr. Smith worked at FBR Capital Markets on the biotechnology team, covering large-, mid-, and small-cap companies. Mr. Smith began his career at Bloomberg, where he held roles of increasing responsibility, including coverage of biotech and specialty pharmaceutical sectors for Bloomberg Intelligence. Prior to covering Immunology and Metabolism, Mr. Smith was a key member of the Firm’s Targeted Oncology team.

Mr. Smith earned a B.S. in Finance and Psychology from The College of New Jersey.

Puneet Souda is a Senior Research Analyst at Leerink Partners covering Life Science Tools and Diagnostics.

Prior to joining the Firm in 2014, Mr. Souda was a Senior Associate at Citigroup covering Medical Devices. Before joining Wall Street, Mr. Souda spent over a decade in core and basic research labs at UCLA and Purdue University. In this work, he was a customer and collaborator of many Life Science Tools and Diagnostic companies. Mr. Souda has direct experience in the acquisition, management, and utilization of many life sciences technologies for molecular analysis and diagnostics. He has co-authored over 45 peer-reviewed scientific papers and has built an extensive network of colleagues and collaborators among academic lab researchers and Life Science Tools suppliers.

Mr. Souda earned a BA in Biology from Purdue University, undertook graduate study in biotechnology, and earned an MBA from the University of California, San Diego.

Jim Kelly is a Senior Managing Director, Director of Research at Leerink Partners. Mr. Kelly is responsible for product management, analyst development and equity strategy.

Prior to joining Leerink Partners in 2015, Mr. Kelly worked at Credit Suisse, where he served in research management as an Associate Director of Equity Research in New York and was responsible for leading key, strategic initiatives in research product and process development. Prior to his ADOR role at Credit Suisse, Mr. Kelly spent 13 years in Equity Research covering the US Pharmaceuticals industry for Lehman Brothers, Goldman Sachs and Credit Suisse First Boston.

Mr. Kelly received his M.B.A. from Columbia Business School and earned his B.S. in Mechanical Engineering from Lehigh University.  Mr. Kelly also serves on the board of the Lehigh Business School Dean’s Advisory Council.

Christian Clark is the Associate Director of Research at Leerink Partners. He is responsible for product management, equity strategy and for leading key strategic initiatives. Prior to this role, Christian was the firm’s Business Manager of the Healthcare Services & Technology and MD&D investment banking team where he was responsible for managing the group’s overall operations including strategic planning, financial and business reporting and analytics, people management and recruiting.

Prior to Leerink Partners, Mr. Clark worked at Credit Suisse and held a variety of business and strategy positions within the Equities division. Prior to this role, he was a Fixed Income client consultant at Bloomberg LP.

Mr. Clark earned his B.S. in Finance (Summa Cum Laude) from Pennsylvania State University.